Propanc Biopharma Stock Price To Earnings To Growth
| PPCB Stock | USD 0.0002 0.0001 33.33% |
Propanc Biopharma fundamentals help investors to digest information that contributes to Propanc Biopharma's financial success or failures. It also enables traders to predict the movement of Propanc Pink Sheet. The fundamental analysis module provides a way to measure Propanc Biopharma's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Propanc Biopharma pink sheet.
Propanc |
Propanc Biopharma Company Price To Earnings To Growth Analysis
Propanc Biopharma's PEG Ratio indicates the potential value of an equity instrument and is calculated by dividing Price to Earnings (P/E) ratio into earnings growth rate. Most analysts and investors prefer this measure to a Price to Earnings (P/E) ratio because it incorporates the future growth of a firm. The low PEG ratio usually implies that an equity instrument is undervalued; whereas PEG of 1 may indicate that an equity is reasonably priced under given expectations of future growth.
Generally speaking, PEG ratio is a 'quick and dirty' way to measure how the current price of a firm's stock relates to its earnings and growth rate. The main benefit of using PEG ratio is that investors can compare the relative valuations of companies within different industries without analyzing their P/E ratios.
| Competition |
Based on the latest financial disclosure, Propanc Biopharma has a Price To Earnings To Growth of 0.0 times. This is 100.0% lower than that of the Biotechnology sector and 100.0% lower than that of the Health Care industry. The price to earnings to growth for all United States stocks is 100.0% higher than that of the company.
Did you try this?
Run Financial Widgets Now
Financial WidgetsEasily integrated Macroaxis content with over 30 different plug-and-play financial widgets |
| All Next | Launch Module |
Propanc Fundamentals
| Return On Asset | -13.07 | |||
| Current Valuation | 1.53 M | |||
| Shares Outstanding | 1.76 B | |||
| Shares Owned By Insiders | 1.60 % | |||
| Price To Earning | (0.04) X | |||
| EBITDA | (2.14 M) | |||
| Net Income | (2.66 M) | |||
| Cash And Equivalents | 4.07 K | |||
| Total Debt | 1.1 M | |||
| Book Value Per Share | (0) X | |||
| Cash Flow From Operations | (1.44 M) | |||
| Earnings Per Share | (0.09) X | |||
| Target Price | 1.52 | |||
| Beta | 1.42 | |||
| Market Capitalization | 705.56 K | |||
| Total Asset | 81.65 K | |||
| Z Score | -85.8 | |||
| Net Asset | 81.65 K |
About Propanc Biopharma Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Propanc Biopharma's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Propanc Biopharma using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Propanc Biopharma based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Other Information on Investing in Propanc Pink Sheet
Propanc Biopharma financial ratios help investors to determine whether Propanc Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Propanc with respect to the benefits of owning Propanc Biopharma security.